Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transcriptional Shift Identifies a Set of Genes Driving Breast Cancer Chemoresistance

10 Jan 2013

Abstract excerpt

BACKGROUND: Distant recurrences after antineoplastic treatment remain a serious problem for breast cancer clinical management, which threats patients' life. Systemic therapy is administered to eradicate cancer cells from the organism, both at the site of the primary tumor and at any other potential location. Despite this intervention, a significant proportion of breast cancer patients relapse even many years...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bioinformatics and Genomic Networks
Share to Breast Cancer Treatment Studies
Share to Cancer Cells and Metastasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23326553
DOI: 10.1371/journal.pone.0053983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transcriptional Shift Identifies a Set of Genes Driving Breast Cancer ChemoresistancePMID 23326553Read ↗

Deciphering the gene regulatory circuitry governing chemoresistance in Triple-Negative Breast CancerSemantic proximity Read ↗

Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancerSemantic proximity Read ↗

Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance BiomarkersSemantic proximity Read ↗

Decoding gene regulatory circuitry underlying TNBC chemoresistance reveals biomarkers for therapy response and therapeutic targetsSemantic proximity Read ↗

Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to LetrozoleSemantic proximity Read ↗

Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goalsSemantic proximity Read ↗

Microarray-Based Gene Expression Profiling for Molecular Classification of Breast Cancer and Identification of New Targets for TherapySemantic proximity Read ↗

Molecular basis for therapy resistanceSemantic proximity Read ↗

Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerSemantic proximity Read ↗

Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying Anthracycline Therapy Resistance in Breast Cancer.Semantic proximity Read ↗

Gene expression before and after neoadjuvant chemotherapy or endocrine therapy and survival outcomes in hormone receptor-positive, HER2-negative breast cancer: the NEOENDO studySemantic proximity Read ↗

Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc CohortSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.